Who are Candesartan/HCT's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Irbesartan - Hydrochlorothiazide, Candesartan Thiazide, Fimasartan/HCTZ combination, Irbesartan/HCTZ.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/candesartan-hct.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Candesartan/HCT — Competitive Intelligence Brief

Candesartan/HCT (Candesartan/HCT) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor blocker / Thiazide diuretic combination. Area: Cardiovascular.

marketed Angiotensin II receptor blocker / Thiazide diuretic combination AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Candesartan/HCT (Candesartan/HCT) — Population Health Research Institute. Candesartan blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide acts as a diuretic to reduce fluid volume.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Candesartan/HCT TARGET	Candesartan/HCT	Population Health Research Institute	marketed	Angiotensin II receptor blocker / Thiazide diuretic combination	AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter
Irbesartan - Hydrochlorothiazide	Irbesartan - Hydrochlorothiazide	Sanofi	marketed	Angiotensin II receptor blocker / Thiazide diuretic combination	AT1 receptor (angiotensin II type 1 receptor) / Sodium-chloride cotransporter
Candesartan Thiazide	Candesartan Thiazide	Institut de Recherches Cliniques de Montreal	marketed	Angiotensin II receptor blocker / Thiazide diuretic combination	AT1 receptor (angiotensin II type 1 receptor); thiazide-sensitive sodium-chloride cotransporter
Fimasartan/HCTZ combination	Fimasartan/HCTZ combination	Boryung Pharmaceutical Co., Ltd	phase 3	Angiotensin II receptor blocker / Thiazide diuretic combination	AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter
Irbesartan/HCTZ	Irbesartan/HCTZ	Bristol-Myers Squibb	phase 3	Angiotensin II receptor blocker / Thiazide diuretic combination	AT1 receptor (angiotensin II type 1 receptor) / Sodium-chloride cotransporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor blocker / Thiazide diuretic combination class)

Boryung Pharmaceutical Co., Ltd · 1 drug in this class
Bristol-Myers Squibb · 1 drug in this class
Institut de Recherches Cliniques de Montreal · 1 drug in this class
Population Health Research Institute · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Candesartan/HCT — Competitive Intelligence Brief. https://druglandscape.com/ci/candesartan-hct. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab